Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers

Clinical Cancer Research

Volumn 12, Issue 13, 2006, Pages 4072-4079

  Xu, Yi ^a   Dalrymple, Susan L ^a   Becker, Robyn E ^a   Denmeade, Samuel R ^a   Isaacs, John T ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

20ALPHA DIHYDROPROGESTERONE; ANDROGEN; DUTASTERIDE; EPRISTERIDE; FINASTERIDE; STEROID 5ALPHA REDUCTASE INHIBITOR; TESTOSTERONE;

ANDROGEN METABOLISM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CASTRATION; CELL STRAIN LNCAP; CONTROLLED STUDY; DOSE RESPONSE; DRUG HALF LIFE; DRUG INHIBITION; DRUG STRUCTURE; ENZYME ANALYSIS; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; REAL TIME POLYMERASE CHAIN REACTION; TUMOR XENOGRAFT;

ADMINISTRATION, ORAL; ANIMALS; AZASTEROIDS; CELL LINE, TUMOR; CELL PROLIFERATION; CHROMATOGRAPHY, LIQUID; DIHYDROTESTOSTERONE; DISEASE MODELS, ANIMAL; ENZYME ACTIVATION; ENZYME INHIBITORS; FINASTERIDE; GENE EXPRESSION PROFILING; HUMANS; MALE; MASS SPECTROMETRY; MICE; MICE, NUDE; MOLECULAR CONFORMATION; PROSTATIC NEOPLASMS; PROTEIN ISOFORMS; RATS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; STRUCTURE-ACTIVITY RELATIONSHIP; TESTOSTERONE 5-ALPHA-REDUCTASE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33746047132     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-0184     Document Type: Article

References (45)

1. Litvinov IV, De Marzo AM, Isaacs JT. Is the Achilles' heel for prostate cancer therapy a gain of function in androgen receptor signaling? J Clin Endocrinol Metab 2003;88:2972-82.
2. Ellis WJ, Isaacs JT. Effectiveness of complete versus partial androgen withdrawal therapy for the treatment of prostatic cancer as studied in the Dunning R-3327 system of rat prostatic adenocarcinomas. Cancer Res 1985;45:6041-50.
3. Kyprianou N, Isaacs JT. Quantal relationship between prostatic dihydrotestosterone and prostatic cell content: critical threshold concept. Prostate 1987;11:41-50.
4. Isaacs JT. Role of androgens in prostatic cancer. Vitam Horm 1994;49:433-502.
5. Russell DW, Wilson JD. Steroid 5α-reductase: two genes/two enzymes. Annu Rev Biochem 1994;63:25-61.
6. van Weerden WM, van Steenbrugge GJ, van Kreuningen A, Moerings EP, de Jong FH, Schroder FH. Assessment of the critical level of androgen for growth response of transplantable human prostatic carcinoma (PC-82) in nude mice. J Urol 1991;145:631-4.
7. Lamb JC, Levy MA, Johnson RK, Isaacs JT. Response of rat and human prostatic cancers to the novel 5α-reductase inhibitor, SK&F 105657. Prostate 1992;21:15-34.
8. Wei GL, Xiao SH, Liu CX. Pharmacokinetics of epristeride in rats and beagle dogs. Yao Xue Xue Bao 2000;35:721-4.
9. Benincosa LJ, Audet PR, Lundberg D, Zariffa N, Jorkasky DK. Pharmacokinetics and absolute bioavailability of epristeride in healthy male subjects. Biopharm Drug Dispos 1996;17:249-58.
10. Levy MA, Brandt M, Sheedy KM, et al. Cloning, expression and functional characterization of type 1 and type 2 steroid 5α-reductases from cynomolgus monkey: comparisons with human and rat isoenzymes. J Steroid Biochem Mol Biol 1995;52:307-19.
11. McNulty AM, Audia JE, Bemis KG, Goode RL, Rocco VP, Neubauer BL. Kinetic analysis of LY320236: competitive inhibitor of type I and non-competitive inhibitor of type II human steroid 5ct-reductase. J Steroid Biochem Mol Biol 2000;72:13-21.
12. 14C] finasteride after oral administration in humans. Drug Metab Dispos 1992;20:148-55.
13. Ohtawa M, Morikawa H, Shimazaki J. Pharmacokinetics and biochemical efficacy after single and multiple oral administration of N-(2-methyl-2-propyl)- 3-oxo-4-aza-5α-androst-1-ene-17β-carboxamide, a new type of specific competitive inhibitor of testosterone 5α-reductase, in volunteers. Eur J Drug Metab Pharmacokinet 1991;16:15-21.
14. Tian G, Mook RA, Jr., Moss ML, Frye SV. Mechanism of time-dependent inhibition of 5α-reductases by Δ1-4-azasteroids: toward perfection of rates of time-dependent inhibition by using ligand-binding energies. Biochemistry 1995;34:13453-9.
15. Gisleskog PO, Hermann D, Hammarlund-Udenaes M, Karlsson MO. The pharmacokinetic modelling of GI198745 (dutasteride), a compound with parallel linear and nonlinear elimination. Br J Clin Pharmacol 1999;47:53-8.
16. Ju XB, Wu HF, Hua LX, Zhang W, Li J. The clinical efficacy of epristeride in the treatment of benign prostatic hyperplasia. Zhonghua Nan Ke Xue 2002;8:42-4.
17. Hudson PB, Boake R, Trachtenberg J, et al. Efficacy of finasteride is maintained in patients with benign prostatic hyperplasia treated for 5 years. The North American Finasteride Study Group. Urology 1999;53:690-5.
18. McConnell JD, Wilson JD, George FW, Geller J, Pappas F, Stoner E. Finasteride, an inhibitor of 5α-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia. J Clin Endocrinol Metab 1992;74:505-8.
19. Debruyne F, Barkin J, van Erps P, Reis M, Tammela TL, Roehrborn C. Efficacy and safety of long-term treatment with the dual 5α-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia. Eur Urol 2004;46:488-94; discussion 495.
20. Clark RV, Hermann DJ, Cunningham GR, Wilson TH, Morrill BB, Hobbs S. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5α-reductase inhibitor. J Clin Endocrinol Metab 2004;89:2179-84.
21. Presti JC, Jr., Fair WR, Andriole G, et al. Multicenter, randomized, double-blind, placebo controlled study to investigate the effect of finasteride (MK-906) on stage D prostate cancer. J Urol 1992;148:1201-4.
22. Andriole G, Lieber M, Smith J, et al. Treatment with finasteride following radical prostatectomy for prostate cancer. Urology 1995;45:491-7.
23. Stuart JD, Frank WL, Noel DS, et al. Pharmacokinetic parameters and mechanisms of inhibition of rat type 1 and 2 steroid 5α-reductases: determinants for different in vivo activities of GI198745 and finasteride in the rat. Biochem Pharmacol 2001;62:933-42.
24. Tian G. In vivo time-dependent inhibition of human steroid 5α-reductase by finasteride. J Pharm Sci 1996;85:106-11.
25. Ishii Y, Mukyama H, Ohtawa M. In vitro biotransformation of finasteride in rat hepatic microsome: isolation and characterization of metabolites. Drug Metab Dispos 1994;22:79-84.
26. Brendler CB, Follansbee AL, Isaacs JT. Discrimination between normal, hyperplastic and malignant human prostatic tissues by enzymatic profiles. J Urol 1985;133:495-501.
27. Bonkhoff H, Stein U, Aumuller G, Remberger K. Differential expression of 5α-reductase isoenzymes in the human prostate and prostatic carcinomas. Prostate 1996;29:261-7.
28. Luo J, Dunn TA, Ewing CM, Walsh PC, Isaacs WB. Decreased gene expression of steroid 5α-reductase 2 in human prostate cancer: implications for finasteride therapy of prostate carcinoma. Prostate 2003;57:134-9.
29. Thomas LN, Lazier CB, Gupta R, et al. Differential alterations in 5α-reductase type 1 and type 2 levels during development and progression of prostate cancer. Prostate 2005;63:231-9.
30. Titus MA, Gregory CW, Ford OH III, Schell MJ, Maygarden SJ, Mohler JL. Steroid 5α-reductase isozymes I and II in recurrent prostate cancer. Clin Cancer Res 2005;11:4365-71.
31. Deslypere JP, Young M, Wilson JD, McPhaul MJ. Testosterone and 5-αadihydrotestosterone interact differently with the androgen receptor to enhance transcription of the MMTA-CAT reporter gene. Mol Cell Endocrinol 1992;88:15-22.
32. Brooks JR, Berman C, Nguyen H, et al. Effect of castration, DES, flutamide and the 5α-reductase inhibitor, MK906, on the growth of the Dunning rat prostatic carcinoma, R-3327. Prostate 1991;18:215-27.
33. Isaacs JT, Isaacs WB, Feitz WFJ, Scheres J. Establishment and characterization of seven Dunning rat prostatic cancer cell lines and their use in developing methods for predicting metastatic abilities of prostatic cancers. Prostate 1986;9:261-81.
34. van Bokhoven A, Varella-Garcia M, Korch C, et al. Molecular characterization of human prostate carcinoma cell lines. Prostate 2003;57:205-25.
35. Dalrymple S, Antony L, Xu Y, et al. Role of notch-1 and E-cadherin in the differential response to calcium in culturing normal versus malignant prostate cells. Cancer Res 2005;65:9269-79.
36. Azzolina B, Ellsworth K, Andersson S, Geissler W, Bull HG, Harris GS. Inhibition of rat α-reductases by finasteride: evidence for isozyme differences in the mechanism of inhibition. J Steroid Biochem Mol Biol 1997;61:55-64.
37. Soderstrom TG, Bjelfman C, Brekkan E, et al. Messenger ribonucleic acid levels of steroid 5α-reductase 2 in human prostate predict the enzyme activity. J Clin Endocrinol Metab 2001;86:855-8.
38. Shirakawa T, Okada H, Acharya B, et al. Messenger RNA levels and enzyme activities of 5α-reductase types 1 and 2 in human benign prostatic hyperplasia (BPH) tissue. Prostate 2004;58:33-40.
39. Smith CM, Ballard SA, Worman N, Buettner R, Masters JRW. 5α-Reductase expression by prostate cancer cell lines and benign prostatic hyperplasia in vitro. J Clin Endocrinol Metab 1996;81:1361-6.
40. Bramson HN, Hermann D, Batchelor KW, Lee FW, James MK, Frye SV. Unique preclinical characteristics of GG745, a potent dual inhibitor of 5AR. J Pharmacol Exp Ther 1997;282:1496-502.
41. Lazier CB, Thomas LN, Douglas RC, Vessey JP, Rittmaster RS. Dutasteride, the dual 5α-reductase inhibitor, inhibits androgen action and promotes cell death in the LNCaP prostate cancer cell line. Prostate 2004;58:130-44.
42. Gao J, Arnold JT, Isaacs JT. Conversion from a paracrine to an autocrine mechanism of androgen-stimulated growth during malignant transformation of prostatic epithelial cells. Cancer Res 2001;61:5038-44.
43. Ornstein DK, Smith DS, Andriole GL. Biochemical response to testicular androgen ablation among patients with prostate cancer for whom flutamide and/or finasteride therapy failed. Urology 1998;52:1094-7.
44. Titus MA, Schell MJ, Lih FB, Tomer KB, Mohler JL. Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin Cancer Res 2005;11:4653-7.
45. Singh P, Uzgare A, Litvinov I, Isaacs JT. Combinatorial androgen receptor targeted (i.e., CART) therapy for prostate cancer. Endocr Relat Cancer. In press 2006.